Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Gemcitabine and Protracted 5-Fluorouracil Infusion as Third-line Chemotherapy in Refractory Colorectal Cancer Patients

RAFFAELLA BITOSSI, CARLA MARIA SCULLI, MARCO TAMPELLINI, IRENE ALABISO, MARIA PIA BRIZZI, ANNA FERRERO, AZZURRA OTTONE, ELISA BELLINI, GABRIELLA GORZEGNO, ALFREDO BERRUTI and LUIGI DOGLIOTTI
Anticancer Research September 2008, 28 (5B) 3055-3060;
RAFFAELLA BITOSSI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CARLA MARIA SCULLI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARCO TAMPELLINI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marco.tampellini@unito.it
IRENE ALABISO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA PIA BRIZZI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANNA FERRERO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AZZURRA OTTONE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ELISA BELLINI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GABRIELLA GORZEGNO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALFREDO BERRUTI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUIGI DOGLIOTTI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: There is no standard treatment for patients with advanced colorectal cancer (CRC) progressing after irinotecan and oxaliplatin treatment and having good performance status (PS). Patients and Methods: We investigated gemcitabine 1,000 mg/m2 days 1, 8 and 15 q28d combined with protracted 5-fluorouracil continuous infusion at 200 mg/m2/day, in 37 consecutive patients progressing after oxaliplatin-irinotecan-containing chemotherapies. Results: Partial response (PR) was achieved in 4 (10.8%) and disease stabilization (SD) in 19 (51.4%) cases (PR+SD: 62.2%). Median time to progression and survival were 4.2 and 8.9 months, respectively. Grade III toxicities were thrombocytopenia, neutropenia (in 3 patients) and mucositis (in 2 patients). Clinical benefit was observed in 18 patients (48.6% of the entire population; 64.3% of those patients with PS>0 at study entry). Conclusion: The combination of gemcitabine and 5-fluorouracil continuous infusion was found to be an active and manageable palliative regimen for heavily pre-treated patients with metastatic CRC.

  • Colorectal cancer
  • 5-fluorouracil
  • gemcitabine
  • metastatic disease

Footnotes

  • Received April 3, 2008.
  • Revision received June 19, 2008.
  • Accepted July 1, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (5B)
Anticancer Research
Vol. 28, Issue 5B
September-October 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Gemcitabine and Protracted 5-Fluorouracil Infusion as Third-line Chemotherapy in Refractory Colorectal Cancer Patients
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Gemcitabine and Protracted 5-Fluorouracil Infusion as Third-line Chemotherapy in Refractory Colorectal Cancer Patients
RAFFAELLA BITOSSI, CARLA MARIA SCULLI, MARCO TAMPELLINI, IRENE ALABISO, MARIA PIA BRIZZI, ANNA FERRERO, AZZURRA OTTONE, ELISA BELLINI, GABRIELLA GORZEGNO, ALFREDO BERRUTI, LUIGI DOGLIOTTI
Anticancer Research Sep 2008, 28 (5B) 3055-3060;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Gemcitabine and Protracted 5-Fluorouracil Infusion as Third-line Chemotherapy in Refractory Colorectal Cancer Patients
RAFFAELLA BITOSSI, CARLA MARIA SCULLI, MARCO TAMPELLINI, IRENE ALABISO, MARIA PIA BRIZZI, ANNA FERRERO, AZZURRA OTTONE, ELISA BELLINI, GABRIELLA GORZEGNO, ALFREDO BERRUTI, LUIGI DOGLIOTTI
Anticancer Research Sep 2008, 28 (5B) 3055-3060;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Gemcitabine and Capecitabine for Heavily Pre-treated Metastatic Colorectal Cancer Patients - A Phase II and Translational Research Study
  • Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study
  • The diversity of sex steroid action: the role of micro-RNAs and FOXO transcription factors in cycling endometrium and cancer
  • The Efficacy of Gemcitabine as Salvage Treatment in Patients with Refractory Advanced Colorectal Cancer (CRC): A Single Institution Experience
  • Google Scholar

More in this TOC Section

  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire